Key Highlights

  • ASND shares rose 6.87% today to $264.93, up from a previous close of $247.91.
  • Ascendis and BioMarin entered a binding term sheet resolving all litigation tied to YUVIWEL and navepegritide.
  • Ascendis will pay royalties of 20% in the United States and 18% in the European Union, South Korea, and Brazil on YUVIWEL net sales through May 2030.
  • The company reiterated guidance for more than 500 million euros in 2026 Operating Cash Flow and a 2030 Revenue target of 5 billion euros.
  • Market Capitalization stood at approximately 16.46 billion dollars following the move.

Settlement Removes Legal Overhang Tied to YUVIWEL

Ascendis Pharma A/S (NASDAQ:ASND) shares rose 6.87% today to $264.93 after the company announced a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. related to YUVIWEL and navepegritide-related products. The agreement resolves all outstanding litigation and disputes between the two companies.

Ascendis is a Denmark-based biopharmaceutical company built around its proprietary TransCon technology platform, which it uses to develop therapies for rare endocrinology disorders and select oncology programs. The company is headquartered in Hellerup, Denmark, with additional operations across Europe and the United States.

Under the terms of the agreement, BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing license allowing continued research, development, manufacturing, and commercialization of navepegritide-related products without restriction. BioMarin will also waive certain regulatory exclusivities, dismiss all proceedings, and provide a covenant not to sue related to the covered intellectual property. In exchange, Ascendis will dismiss its proceedings against BioMarin and pay royalties on YUVIWEL net sales of 20% in the United States and 18% in the European Union, South Korea, and Brazil, running from the first commercial sale in each country through May 20, 2030.

Guidance Reiterated as YUVIWEL Uptake Continues

YUVIWEL, known generically as navepegritide, was approved by the FDA in February 2026 to increase linear growth in pediatric patients with achondroplasia. A decision from the European Medicines Agency on the company's Marketing authorization application is anticipated in the fourth quarter of 2026. Ascendis reiterated its expectation of generating more than 500 million euros in operating cash flow in 2026 and reaffirmed a longer-term target of 5 billion euros in revenue by 2030.

Ascendis carries a market capitalization of approximately 16.46 billion dollars, with a trailing price to Earnings ratio near 19.94. The stock has traded in a 52-week range of $186.05 to $282.15. Some research firms have adjusted price targets following the announcement while maintaining favorable ratings on the stock, reflecting continued Buy-Side interest even as the legal resolution removes a previously cited overhang.

What Comes Next for Ascendis

The settlement with BioMarin removes a significant legal uncertainty that had weighed on Ascendis shares, clearing the path for continued commercialization of YUVIWEL without the risk of injunctive relief or damages tied to the dispute. Investors will watch for the European Medicines Agency's decision later this year and continued sales trends for YUVIWEL as key markers of the company's progress toward its 2030 revenue target.